PDCD1 and neoplasm: Although it is not clear whether PD-1 and LAG-3 share the same mechanisms of action, it has been reported synergy between LAG-3 and PD-1 to inhibit effector immune responses (75), as a high percentage of LAG-3+ and LAG-3− tumor-infiltrating CD8+ T cells expressing PD-1 has been observed (76).